26
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study

, , , , , , , , , , , , , , , , , & ORCID Icon show all
Pages 1389-1402 | Received 31 Jan 2024, Accepted 03 Jul 2024, Published online: 09 Jul 2024
 

Abstract

Background

The dominant artery blood supply is a characteristic of hepatocellular carcinoma (HCC). However, it is not known whether the blood supply can predict the post-hepatectomy prognosis of patients with HCC. This retrospective study investigated the prognostic value of the portal venous and arterial blood supply estimated on triphasic liver CT (as a portal venous coefficient, PVC, and hepatic arterial coefficient, HAC, respectively) in patients with HCC following hepatectomy.

Methods

HCC patients who were tested by triphasic liver CT 2 weeks before hepatectomy and received R0 hepatectomy at the Second Affiliated Hospital, Kunming Medical University between January 1, 2016 and December 31, 2020, were retrospectively screened. Their PVC and HAC, and other variables were analyzed for the prediction of overall survival (OS) and recurrence-free survival (RFS) using the least absolute shrinkage and selection operator and Cox proportional hazard regression models.

Results

Four hundred and nineteen patients (53.2 ± 10.6 years of age and 370 men) were evaluated. A shorter OS was independently associated with higher blood albumin and total bilirubin grade [hazard ratio (HR) 2.020, 95% confidence interval (CI) 1.534–2.660], higher Barcelona Clinic Liver Cancer (BCLC) stage (HR 1.514, 95% CI 1.290–1.777), PVC ≤ 0.386 (HR 1.628, 95% CI 1.149–2.305), and HAC > 0.029 (HR 1.969, 95% CI 1.380–2.809). A shorter RFS was independently associated with male (HR 1.652, 95% CI 1.005–2.716), higher serum α-fetoprotein ≥ 400 ng/mL (HR 1.672, 95% CI 1.236–2.263), higher BCLC stage (HR 1.516, 95% CI 1.300–1.768), tumor PVC ≤ 0.386 (HR 1.641, 95% CI 1.198–2.249), and tumor HAC > 0.029 (HR 1.455, 95% CI 1.060–1.997).

Conclusion

Tumor PVC or HAC before hepatectomy is valuable for independently predicting postoperative survival of HCC patients.

Graphical Abstract

Abbreviations

ALBI grade, albumin, and total bilirubin grade; BCLC stage, Barcelona Clinic Liver Cancer stage; CI, confident interval; CT, computed tomography; HAC, hepatic arterial coefficient; HCC, hepatocellular carcinoma; HR, hazards ratio; IQR, inter-quartile range; LASSO, least absolute shrinkage selection operator; PVC, portal venous coefficient; OS, overall survival; RFS, recurrence-free survival; ROI, regions of interest; TACE, transcatheter arterial chemoembolization.

Data Sharing Statement

The datasets used and/or analyzed during the current study and the CALVIS LIVER PERFUSION software are available from the corresponding author Y.K. upon reasonable request.

Ethics Approval and Informed Consent

This study was approved by the Committee of Ethics at the Second Affiliated Hospital, Kunming Medical University (Shen-PJ-Ke-2022-60). Written informed consent was waived by the Committee of Ethics as its retrospective collection.

Acknowledgments

The current affiliation of Dr. Yu-Shan Wu is Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, SC, China. The current affiliation of Dr. Wei-Hu Zhang is Department of Radiology, Northeast Yunnan Regional Central Hospital, Zhaotong 657000, YN, China.

Disclosure

All authors declare that they have no competing interests in this work.

Additional information

Funding

The study was supported by grants to Y.K. from National Natural Science Foundation of China for Young Scholars (#82103173), the Yunnan Province Young and Middle Scholarly and Technical Leader-B Program (#202205AC160063), the Yunnan Fundamental Research Project for Excellent Young Scholars (202401AW070003), the Yunnan Province Sci-Tech Department-KMU Applied Basic Research Co-Fund (#202001AY070001-147), the National Innovative and Entrepreneurial Training Program for College Students (#202310678026X, #202210678012, #202210678014X, and #202110678049X), the Kunming Medical University Innovative Program for Postgraduate (#2024S305), and the Kunming Medical University Innovative Experiment Program for College Students (2024CYD022, 2024CYD045); a grant to J.P.W. from the Internal Institution Research in Clinical Medicine (#2020ynlc011); a grant to Y.H.L. from the Yunnan Province Sci-Tech Department-KMU Applied Basic Research Co-Fund (#202001AY070001-059); a grant to S.Q.H. from the Yunnan Province Sci-Tech Department-KMU Applied Basic Research Co-Fund (#202301AY070001-235); and a grant to Y.W. from the Collaborative Research Program of the Second Affiliated Hospital of Kunming Medical University (#2022dwhz13).